logo
Kansas advocate warns federal cuts to Medicaid will accelerate maternal deaths

Kansas advocate warns federal cuts to Medicaid will accelerate maternal deaths

Yahoo13-06-2025
From left, Hadiya Toney and Sapphire Garcia appear at Liberation Place, a mutual aid hub that distributes sexual and reproductive health supplies and baby items in Wichita. Toney is community care coordinator at Liberation Place and Garcia is executive director and founder of the Kansas Birth Justice Society. (Submitted)
TOPEKA — More Kansans will die during pregnancy and childbirth as a result of proposed federal cuts to Medicaid, says the leader of a state organization focused on maternal health equity.
A new analysis of cuts contained in the GOP's 'big beautiful bill' under consideration by Congress shows that 13,000 Kansans would lose enrollment in Medicaid, and the state would lose $3.77 billion in federal funding.
Sapphire Garcia, executive director and founder of the Kansas Birth Justice Society, said the gutting of Medicaid funding would decimate perinatal care systems and accelerate maternal mortality. The burden, she said, would fall hardest on those who already face steep inequities — Black, Indigenous, rural and low-income Kansans.
Advocates 'on the front lines of this crisis' already are exhausted, she said.
'We are tired of fighting a system that continues to ignore our pleas while our communities are left grieving unbearable losses,' Garcia said. 'We hold space for families who have buried their babies, their partners, their birthing people — and then we're asked to carry on as if that grief is not the result of policy choices. But it is.'
Garcia's comments followed a panel discussion Thursday organized by the United Methodist Health Ministry Fund. The discussion centered on a recent report on access to maternal health care in Kansas and an analysis by Manatt Health of proposed federal cuts to Medicaid.
The report on maternity care access, which was produced by the Kansas Center for Rural Health with funding from the United Methodist Health Ministry Fund, found that most Kansans don't have local access to inpatient maternity care. Most Kansas counties don't even have an OB-GYN, and only eight counties have more than five OB-GYNs, the report found.
One of the panelists, Beth Oller, family medicine physician at Rooks County Health Center, said it is difficult to get physicians to move to rural areas, where they might have to cover the ER and provide hospice care and other services to support an undeserved community. And most family doctors who graduate residency don't have an interest in providing obstetric care, she said.
For a while, she said, she was one of two OB-GYNs at her health center, and the other wasn't trained for operative deliveries. She spent two years never being off of work because she needed to be available for caesarean sections. Then, the other doctor moved out of state and she couldn't recruit another physician.
As a mother of four, she said, she was 'missing so many things.'
'I was heartbroken when I realized that our maternity unit was going to close,' Oller said. 'However, I couldn't do it anymore alone. I knew it wasn't feasible to keep going that way.'
She said the closest place to Stockton, where she lives, to deliver a baby now is in Hays, about 45 minutes away. Another doctor travels two hours from Salina to provide some prenatal care, she said.
Panelists during Thursday's discussion said access to maternal care is connected to Medicaid, which finances more than 40% of births in the state.
The state's failure to expand Medicaid to serve more low-income families or allocate adequate reimbursement rates for Medicaid services are factors in maternal health deserts and the financial struggles of rural hospitals, they said. GOP leaders in the Legislature for more than a decade have blocked Medicaid expansion, which would have served about 150,000 adults and children and unlocked nearly a billion dollars in annual federal funding. Kansas is one of 10 holdout states that have not expanded the program.
'We need to remember that economics are policy, and policy is a matter of life and death,' Garcia said during the panel discussion. 'The fact that we have not expanded Medicaid has killed birthing people in our state is going to continue to kill birthing people in our state and lead to these poor health outcomes. We need to acknowledge that this is a structural failure of our maternal and health care systems.'
A study published in 2020 by the medical journal Women's Health Issues found that Medicaid expansion resulted in seven fewer maternal deaths per 100,000 live births.
Garcia told Kansas Reflector after the panel discussion that Medicaid expansion is a necessary step toward racial and reproductive justice. But now, she said, the most urgent concern is to protect Medicaid itself.
'If the federal program is slashed, expansion in Kansas becomes meaningless — there will be nothing left to expand,' she said. 'Saving Medicaid must be our top priority, and we also cannot lose sight of the need to expand coverage here in Kansas, where families are still denied basic care due to arbitrary income thresholds and political inaction.'
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Social Factors Affect Access to RSV Prophylaxis in Children
Social Factors Affect Access to RSV Prophylaxis in Children

Medscape

timean hour ago

  • Medscape

Social Factors Affect Access to RSV Prophylaxis in Children

TOPLINE: Only about one third of eligible children born outside the typical respiratory syncytial virus (RSV) season received nirsevimab, a monoclonal antibody for RSV prophylaxis. Older age, Black race, and public insurance were associated with reduced rates of receipt. METHODOLOGY: Researchers conducted a retrospective study to examine how many children born outside the typical RSV season (October to March) received nirsevimab and which factors influenced its receipt, such as age, race, insurance type, and residing in low- vs high-opportunity areas (measured by an index indicating neighborhood features that support child development). They included children younger than 8 months who received care across 32 pediatric primary care practices in Pennsylvania and New Jersey, all of which had nirsevimab available. A total of 7208 eligible children born between April and September 2023 (average age at the start of RSV season, 3.5 months; 49% girls; 51.3% White) were included. All had at least one visit to primary care within 14 days of birth and at least one visit after reaching 8 months of age or after the RSV season ended. TAKEAWAY: Overall, 35% of eligible children received nirsevimab, and uptake varied by practice from 20% to 65%. Of those who received nirsevimab, 53.1% were White and 64.4% had private insurance. Older age was associated with reduced odds of receiving nirsevimab (adjusted odds ratio [aOR], 0.60; 95% CI, 0.58-0.62 for each additional month). Children with low weight at birth had higher odds of receiving nirsevimab (aOR, 1.43; 95% CI, 1.13-1.82). Children who were Black vs White (aOR, 0.53; 95% CI, 0.43-0.65), with public vs private insurance (aOR, 0.79; 95% CI, 0.67-0.92), and living in very low- vs very high-opportunity areas (aOR, 0.70; 95% CI, 0.54-0.91) had significantly lower odds of receiving nirsevimab. Among children fully vaccinated against diphtheria, Haemophilus influenzae type B, poliovirus, Streptococcus pneumoniae, tetanus, and pertussis, 38.7% received nirsevimab. IN PRACTICE: 'The identification of sociodemographic factors associated with receipt of nirsevimab emphasizes the importance of examining the drivers of these disparities to inform interventions designed to ensure more equitable uptake so that all children are protected from RSV,' the authors of the study concluded. SOURCE: This study was led by Mahaa M. Ahmed, MS, of the Clinical Futures at Children's Hospital of Philadelphia in Philadelphia. It was published online on July 17, 2025, in Pediatrics. LIMITATIONS: The data represented practices in only one care network, and the findings may not be generalizable. Infants entering their first RSV season were included, which prevented the evaluation of nirsevimab uptake among children at high risk entering their second season of RSV. This retrospective study used electronic health records and could not capture family preferences, knowledge of nirsevimab, or interactions between families and clinicians during vaccination opportunities. DISCLOSURES: This study received support from the Infectious Diseases Society of America's Grants for Emerging Researchers/Clinicians Mentorship program and the Pediatric Infectious Diseases Society's Supporting Research and Promoting Pediatric ID program. The authors reported having no conflicts of interest. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Wells Fargo Cuts Elevance (ELV) Price Target on Margin Uncertainty
Wells Fargo Cuts Elevance (ELV) Price Target on Margin Uncertainty

Yahoo

time4 hours ago

  • Yahoo

Wells Fargo Cuts Elevance (ELV) Price Target on Margin Uncertainty

Elevance Health, Inc. (NYSE:ELV) ranks among the . Wells Fargo kept its Overweight rating on Elevance Health, Inc. (NYSE:ELV) on July 15, but lowered its price target on the health insurer from $478 to $400. Wells Fargo applied a lower multiple of 10.5x to its 2026 earnings per share projection of $38.05, which is less than the previous multiple of 11.5x. designer491/ Wells Fargo stated that the primary driver of the reduced value multiple was uncertainty regarding margins in the Medicaid, Medicare Advantage (MA), and Health Insurance Exchange (HIX) segments for 2025. The firm also pointed out that there was 'relatively low visibility to improvement in 2026,' especially in the Medicaid and Health Insurance Exchange segments. However, it insisted that Elevance's valuation 'remains compelling once dust settles on estimates.' Elevance Health, Inc. (NYSE:ELV), previously Anthem, Inc., is a leading health-benefits provider in the United States. The company offers medical, pharmaceutical, dental, long-term care, disability, and behavioral health insurance under numerous brands, including Anthem Blue Cross, Blue Shield, Wellpoint, and Carelon. While we acknowledge the potential of ELV as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. Read More: and Disclosure: None.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store